Search Results
Your search for ,iII matches 9601 pages
Showing 151 - 200Combination Regimen Prolongs PFS in dMMR/MSI-H Metastatic Colorectal Cancer
The combination of mFOLFOX6, bevacizumab, and atezolizumab prolonged progression-free survival over atezolizumab monotherapy in the first-line setting for patients with mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) metastatic colorectal cancer, according to findings from...
CKM Syndrome Associated With Increased, Stage-Specific Cancer Risk, Study Finds
Cardiovascular-kidney-metabolic (CKM) syndrome is associated with incremental cancer risk and stage-specific immune-metabolic pathways, according to a study using data from the UK Biobank published by Xiao et al in JACC: CardioOncology. These findings highlight potential prevention targets. In this ...
TOPAZ-1 Post Hoc Analysis Supports Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer
In a post hoc analysis of the global phase III TOPAZ-1 trial published in JAMA Oncology, Oh et al found that the addition of durvalumab to chemotherapy with gemcitabine and cisplatin was associated with long-term survival benefit and a clinically manageable safety profile in patients with...
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
In the phase III KEYNOTE-B15/EV-304 trial, perioperative enfortumab vedotin-ejfv plus pembrolizumab significantly improved event-free survival, overall survival, and pathologic complete response compared with the long-standing standard approach of neoadjuvant cisplatin plus gemcitabine in...
Transplant Consolidation Improves Survival in Primary CNS Lymphoma
In the largest randomized trial in untreated primary central nervous system lymphoma to date, high-dose chemotherapy followed by autologous stem-cell transplantation improved progression-free and overall survival compared with nonmyeloablative consolidation in patients who responded to MATRix...
Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL
In the randomized phase III BRUIN CLL-322 trial, adding fixed-duration pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, to venetoclax-rituximab significantly improved progression-free survival in patients with previously treated chronic lymphocytic leukemia or small lymphocytic ...
Rectal Cancer: AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy
Higher tumor cell density in patients with locally advanced rectal cancer receiving irinotecan-intensified neoadjuvant chemoradiotherapy was associated with improved survival outcomes compared with those treated with standard chemoradiotherapy, according to findings from a post-hoc analysis of the...
MMUD vs MRD Transplantation in the Posttransplant Cyclophosphamide Era
Among patients with high-risk hematologic malignancies who underwent hematopoietic cell transplantation with posttransplant cyclophosphamide, mismatched unrelated donor (MMUD) transplantation was associated with lower relapse rates than matched related donor (MRD) transplantation while showing...
Phase III Trial Finds No Benefit for Magrolimab Combination in Higher-Risk MDS
Patients with previously untreated higher-risk myelodysplastic syndromes (MDS) did not experience improved outcomes with the addition of the anti-CD47 antibody magrolimab to azacitidine compared with azacitidine alone, according to the results of the phase III ENHANCE trial reported by Sallman et...
ELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC
In an interim analysis of the phase III ELEVATE trial reported in The New England Journal of Medicine, Yue et al found that patients with completely resected ALK-positive non–small cell lung cancer (NSCLC) who received adjuvant ensartinib experienced significantly longer disease-free survival than...
Proton Pump Inhibitor, Antibiotic Exposure Linked to Inferior Durvalumab Outcomes in Unresectable Stage III NSCLC
As reported in The Lancet Oncology by Brunetti et al, a post hoc analysis of the phase III PACIFIC trial showed that baseline exposure to proton pump inhibitors and antibiotics was associated with inferior outcomes among patients with unresectable stage III non–small cell lung cancer (NSCLC)...
Dabrafenib Plus Trametinib Improves Progression-Free Survival in BRAF V600E–Positive Differentiated Thyroid Cancer
In a global phase III trial reported in The Lancet Oncology by Gao et al, dabrafenib plus trametinib significantly improved progression-free survival and overall response rate compared with placebo in previously treated patients with locally advanced or metastatic, radioactive iodine–refractory,...
Relapsed or Refractory Multiple Myeloma: Early-Phase Trial Investigates Novel Bispecific Antibody
In a phase I clinical trial, treatment with the investigational FcRH5×CD3 bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma—many of whom had already been through multiple other cancer treatments—and produced a median duration of response of 11.2 months ...
Neoadjuvant Inetetamab Plus Pyrotinib Evaluated in HER2-Positive Locally Advanced Breast Cancer in China
Neoadjuvant treatment with the HER2-targeted monoclonal antibody inetetamab in combination with the irreversible pan-HER tyrosine kinase inhibitor pyrotinib (inhibits HER1, HER2, HER4) and chemotherapy produced high pathologic response rates in patients in China with HER2-positive locally advanced...
Jennifer Gile, MD, on High-Risk DLBCL: frontMIND and POLARIX Regimens
Jennifer Gile, MD, of Willamette Valley Cancer Institute, talks about the first positive phase III trials in the high-risk diffuse large B-cell lymphoma (DLBCL) space—POLARIX and frontMIND. POLARIX established the superiority of a modified regimen of rituximab, cyclophosphamide, doxorubicin,...
Jennifer Gile, MD, on First-Line Treatment of DLBCL: POLARIX Long-Term Update and Implications
Jennifer Gile, MD, of Willamette Valley Cancer Institute, reviews findings from the POLARIX study, a double-blind, placebo-controlled, international phase III trial that evaluated pola-R-CHP—a modified regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), in...
POLARGO Trial Shows Survival Benefit With Polatuzumab Vedotin–Based Regimen in Relapsed or Refractory DLBCL
According to the results of the phase III POLARGO trial reported by Matasar et al in the Journal of Clinical Oncology, adding polatuzumab vedotin-piiq to rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) significantly improved overall survival compared with standard rituximab, gemcitabine, and ...
ASCO 2026: Multiple Myeloma Studies Highlight Advances Across the Field
The plasma cell dyscrasia oral abstract session at the 2026 ASCO Annual Meeting featured several pivotal trials that advanced the field, including those highlighted here. Coverage of new treatments for amyloidosis will appear in a separate article. Mezigdomide-Based Regimen Improves...
Early Research Examines Daraxonrasib in NRAS-Mutant Melanoma
A research team has reported that a groundbreaking pathway-targeted therapy may be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease. Martin McMahon, PhD, Senior Director of Preclinical Translation at Huntsman Cancer Institute...
Benjamin P. Levy, MD, on KRAS G12C–Mutated NSCLC: Current Treatment Landscape
Benjamin P. Levy, MD, of Johns Hopkins Sidney Kimmel Cancer Center, reviews currently available therapies for patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), noting the importance of genomic testing to identify individuals eligible for treatment with these agents. He discusses...
EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma
Results of the phase III EMERALD-3 trial showed that combining transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE regimen, (single tremelimumab[an anti-cytotoxic T lymphocyte–associated antigen 4] plus regular interval durvalumab [anti–PD-L1]) with or without lenvatinib...
Node-Negative Breast Cancer: 20-Year Outcomes With IM-MS Lymph Node Irradiation
As reported in The Lancet Oncology by Kaidar-Person et al, an unplanned subset analysis at 20 years in the phase III EORTC trial 22922/10925 showed that internal mammary and medial supraclavicular (IM-MS) nodal irradiation was associated with a significantly lower rate of breast cancer...
Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
As reported in The Lancet by Lu et al, an interim analysis of the Chinese phase III HARMONi-6 trial showed that ivonescimab plus chemotherapy was associated with significantly improved overall survival vs tislelizumab plus chemotherapy in patients with previously untreated advanced squamous...
ENDURANCE Trial in Newly Diagnosed Myeloma: No Survival Benefit With Indefinite vs 2 Years of Maintenance Treatment
For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance resulted in more toxicity with no survival benefit from continuing treatment until disease progression compared with stopping after 2 years. Results from the...
Addition of Sacituzumab Tirumotecan to Pembrolizumab in PD-L1–Positive Advanced NSCLC
As reported in The Lancet by Xiong et al, an interim analysis of a Chinese phase III trial (OptiTROP-Lung05) has shown that the addition of sacituzumab tirumotecan (a trophoblast cell–surface antigen 2–targeting antibody-drug conjugate) to pembrolizumab significantly prolonged progression-free...
KRAS G12D–Mutated Metastatic Pancreatic Cancer: Zoldonrasib Plus Chemotherapy
An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown promising early results when combined with standard first-line chemotherapy, according to research presented at the ESMO Gastrointestinal Cancers Congress 2026 (Abstract...
Setmelanotide in Patients With Acquired Hypothalamic Obesity
Setmelanotide, a melanocortin-4 receptor agonist, significantly reduced body mass index (BMI) and signs of hunger in patients with acquired hypothalamic obesity, according to findings from the phase III TRANSCEND trial published in The New England Journal of Medicine. Although focused primarily on...
Radiotherapy Dose Escalation With Intraoperative Radiotherapy vs Surgery Alone in Glioblastoma
In a phase III trial (INTRAGO-II) reported in The Lancet Oncology, Giordano et al found that the addition of intraoperative radiotherapy to surgery did not improve outcomes in patients with newly diagnosed glioblastoma. Study Details The open-label trial enrolled 298 patients (full-analysis set)...
Stage III HER2-Negative Breast Cancer With HRD: Standard Chemotherapy Plus Olaparib
In a European phase III trial (SUBITO) reported in The Lancet Oncology, Seefat et al found that intensified alkylating chemotherapy with autologous stem cell rescue (IACT) provided no overall survival advantage vs standard chemotherapy followed by olaparib in patients with stage IIIA-C...
Perioperative Systemic Therapy vs Surgery Alone in Colorectal Peritoneal-Only Metastases
In a phase III trial (CAIRO6) reported in The Lancet Oncology, Rovers et al found that perioperative systemic therapy was not associated with significant improvement in overall survival vs surgery alone in patients with resectable peritoneal-only metastases of colorectal adenocarcinoma. Study...
Breast Cancer: Tailoring Radiotherapy Based on Nodal Response to Primary Chemotherapy
As reported in The Lancet Oncology by Mauritz et al, 10-year follow-up of a Dutch prospective registry study (RAPCHEM: BOOG 2010–03) indicated that tailoring postoperative locoregional radiotherapy based on nodal response to primary chemotherapy was associated with maintenance of a low locoregional ...
Head and Neck Cancer: Long-Term Follow-up of Postoperative Chemoradiotherapy With Weekly vs Every-3-Week Cisplatin
In the long-term follow-up of a Japanese phase II/III trial (JCOG1008) reported in the Journal of Clinical Oncology, Tahara et al found maintained noninferiority of chemoradiotherapy with weekly vs every-3-week cisplatin for overall survival in patients with postoperative high-risk locally advanced ...
Case 1: Liver-Limited Hepatocellular Carcinoma
This is Part 1 of First-Line HCC in Focus: Survival, Safety, and Real-World Evidence, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, James J. Harding, MD, R. Kate Kelley, MD, and Anthony El-Khoueiry, MD, discuss treatment...
No Survival Benefit From Chemoradiotherapy After D2 Gastrectomy in Gastric Cancer
The addition of radiotherapy to the S-1 plus oxaliplatin (SOX) chemotherapy regimen did not improve disease-free or overall survival in patients with pathologic T4 and/or node-positive gastric adenocarcinoma who underwent D2 gastrectomy (ie, R0 resection with D2 lymphadenectomy), based on a phase...
Previously Untreated Advanced NSCLC With High PD-L1 Expression: PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy?
In a meta-analysis reported in JAMA Oncology, Di Federico et al found that the addition of first-line platinum-based chemotherapy to PD-1/-L1 inhibition was associated with improved outcomes in patients with advanced non–small cell lung cancer (NSCLC) with high PD-L1 expression. Study Details The...
Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative
At a pivotal moment for pancreatic cancer, Break Through Cancer and the Lustgarten Foundation, with support from the Cinelli Family Foundation, has announced a $16 million investment in the Conquering KRAS for Patients with Pancreatic Cancer TeamLab. Spanning six world-class cancer research...
Antonio Llombart-Cussac, MD, PhD, on ADELA: Elacestrant Plus Everolimus in ESR1-Mutated ER-Positive HER2-Negative Advanced Breast Cancer
Antonio Llombart-Cussac, MD, PhD, of Medica Scientia Innovation Research (MEDSIR), discusses the ongoing ADELA study, a double-blind, placebo-controlled, randomized phase III trial of elacestrant plus everolimus vs elacestrant plus placebo in patients with estrogen receptor (ER)-positive...
Paving New ROADS in the Treatment of Brain Metastases With Implanted Tile-Based Radiation Therapy
Tile-based radiation therapy (TBRT) implanted at the time of resection outperformed standard postoperative stereotactic radiation therapy (SRT) in the phase III Radiation One and Done Study (ROADS), improving surgical bed control and overall survival while maintaining a comparable safety profile,...
FDA Approves Capivasertib Plus Abiraterone With ADT/Prednisone in Patients With mHSPC
The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap) in combination with abiraterone and prednisone for the treatment of PTEN-deficient metastatic androgen pathway modulation-naive or sensitive (mAPMN/S) prostate cancer (also referred to as metastatic hormone-sensitive...
Update to ASCO Guideline on Advanced NSCLC Without Driver Alterations Adds Retifanlimab to Treatment Options
ASCO has issued an update to its living guideline on systemic therapies for patients with stage IV NSCLC without driver alterations.1 The update, which includes a new recommendation regarding the PD-1 inhibitor retifanlimab-dlwr and chemotherapy, follows a recent full update to the guideline...
Abemaciclib Reduces Disease Progression, Death in Rare, Aggressive Soft-Tissue Sarcoma
In the treatment of advanced dedifferentiated liposarcoma, a rare and aggressive soft-tissue sarcoma, the CDK4/6 inhibitor abemaciclib significantly reduced the risk of disease progression or death by 62% as compared with placebo in the randomized phase III SARC041 study.1 Mark Dickson, MD, of...
Talquetamab Combinations in Relapsed or Refractory Myeloma
In an interim analysis of a phase III trial (MonumenTAL-3) reported in The New England Journal of Medicine, Mina et al found that the combinations of talquetamab with daratumumab/pomalidomide (Tal-DP) and talquetamab plus daratumumab (Tal-D) improved progression-free survival vs...
Advanced Breast Cancer: Novel CDK4/6 Inhibitor Plus an Aromatase Inhibitor
In an interim analysis of a Chinese phase III trial (FCN-437c-III201) reported in JAMA Oncology, Yuan et al found that the addition of the novel CDK4/6 inhibitor fovinaciclib to aromatase inhibitor therapy was associated with significant improvement in progression-free survival in the first-line...
Chinese Study of HER2-Targeted Combination in Neoadjuvant Therapy for Locally Advanced Breast Cancer
A HER2-targeted regimen produced high pathologic complete response rates before surgery in patients with locally advanced HER2-positive breast cancer, according to results from a single-arm phase II neoadjuvant trial conducted in China. The research was highlighted in a media briefing ahead of the...
Subgroup Analysis of Inavolisib Regimen in Asian Patients With Advanced Breast Cancer
Treatment with the PI3K inhibitor inavolisib in combination with palbociclib and fulvestrant produced substantial clinical benefits in Asian patients with PIK3CA-mutated, hormone receptor–positive (HR-positive), HER2-negative, endocrine-resistant advanced breast cancer, according to a subgroup...
Addition of Mezigdomide to Carfilzomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma
In an interim analysis of a phase III trial (SUCCESOR-2) reported in The Lancet, Dimopoulos et al found that the addition of the cereblon E3 ligase modulator mezigdomide to carfilzomib/dexamethasone significantly improved progression-free survival in previously treated patients with relapsed or...
Ga-68–PSMA-11 PET/CT in Diagnosis of Prostate Cancer
In an Australian phase III noninferiority trial reported in The Lancet Oncology, Buteau et al found that use of gallium-68–labeled PSMA-11 (Ga-68–PSMA-11) positron-emission tomography/computed tomography (PET/CT) could improve the pathway of diagnosis of prostate cancer in men with clinical...
Aumolertinib Plus Chemotherapy in EGFR-Mutated Advanced NSCLC
In a Chinese phase III trial (AENEAS2) reported in The Lancet Oncology, Li et al found that the combination of aumolertinib with chemotherapy significantly improved progression-free survival vs aumolertinib alone in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC). Study...
Jennifer A. Woyach, MD, on Pretreated Relapsed or Refractory CLL/SLL: Ongoing ROCKET-CLL Trial
Jennifer A. Woyach, MD, of The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University, discusses the ongoing, actively recruiting ROCKET-CLL trial, which is a phase III study aiming to compare the efficacy of rocbrutinib vs pirtobrutinib in patients...
Relapsed or Refractory Multiple Myeloma: Talquetamab/Daratumumab
Patients with multiple myeloma who received a new immunotherapy combination had significantly longer progression-free survival and showed early signs of improved overall survival, according to findings from the phase III MonumenTAL-3 trial. Peter M. Voorhees, MD, Professor of Medicine at Wake...
